Active substances
Esomeprazole + Naproxen
- US FDA 6
- Health Canada 6
- NHS prices 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | EQ 20MG BASE;375MG; EQ 20MG BASE;500MG | tablet, delayed release · oral | DR REDDYS | Prescription | 18 Feb 2020 |
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | EQ 20MG BASE;375MG; EQ 20MG BASE;500MG | tablet, delayed release · oral | AJANTA PHARMA LTD | Prescription | 6 Oct 2022 |
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | EQ 20MG BASE;375MG; EQ 20MG BASE;500MG | tablet, delayed release · oral | SCIEGEN PHARMS | Prescription | 11 Oct 2023 |
| VIMOVO | EQ 20MG BASE;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, delayed release · oral | HORIZON | Discontinued | 30 Apr 2010 |
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | EQ 20MG BASE;375MG; EQ 20MG BASE;500MG | tablet, delayed release · oral | PHARMOBEDIENT | Discontinued | 20 Jul 2021 |
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | EQ 20MG BASE;375MG; EQ 20MG BASE;500MG | tablet, delayed release · oral | ACTAVIS LABS FL INC | Discontinued | 24 Aug 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-NAPROXEN / ESOMEPRAZOLE | 02564521 | 20 MG; 375 MG | TABLET (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | APOTEX INC |
| APO-NAPROXEN / ESOMEPRAZOLE | 02564548 | 20 MG; 500 MG | TABLET (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | APOTEX INC |
| MYLAN-NAPROXEN/ESOMEPRAZOLE MR | 02443449 | 500 MG; 20 MG | TABLET (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-NAPROXEN/ESOMEPRAZOLE MR | 02458608 | 375 MG; 20 MG | TABLET (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| VIMOVO | 02361701 | 20 MG; 375 MG | TABLET (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | XEDITON PHARMACEUTICALS INC |
| VIMOVO | 02361728 | 500 MG; 20 MG | TABLET (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | XEDITON PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Naproxen 500mg / Esomeprazole 20mg modified-release tablets | £14.95 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.